Earnings Summary

Verrica Pharmaceuticals Inc’s revenue jumped 2823.53% since last year same period to $1.99Mn in the Q4 2023. On a quarterly growth basis, Verrica Pharmaceuticals Inc has generated -31.85% fall in its revenue since last 3-months.

Verrica Pharmaceuticals Inc’s net profit fell -335.57% since last year same period to $-24.61Mn in the Q4 2023. On a quarterly growth basis, Verrica Pharmaceuticals Inc has generated 0.76% jump in its net profits since last 3-months.

Verrica Pharmaceuticals Inc’s net profit margin jumped 85.1% since last year same period to -1238.13% in the Q4 2023. On a quarterly growth basis, Verrica Pharmaceuticals Inc has generated -45.62% fall in its net profit margins since last 3-months.

Verrica Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.4 - a 24.53% jump from last quarter’s estimates.

Verrica Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.4.

Verrica Pharmaceuticals Inc’s earning per share (EPS) fell -278.57% since last year same period to -0.53 in the Q4 2023. This indicates that the Verrica Pharmaceuticals Inc has generated -278.57% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Verrica Pharmaceuticals Inc’s return on assets (ROA) stands at -0.63.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Verrica Pharmaceuticals Inc’s return on equity (ROE) stands at -2.24.